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Background: Miglitol is an oral anti-diabetic drug that acts by inhibiting carbohydrate absorption in the small intestine.
Recent studies have shown that miglitol reduces obesity in humans and rodents. However, its mechanisms have
remained unclear. The purpose of this study was to determine whether miglitol generates heat by activating uncoupling
protein 1 (UCP1), an enzyme involved in thermogenesis, in brown adipose tissue (BAT) in mice.
Methods: Four-week-old male C57BL/6 J mice were fed a high-fat diet alone (HF) or a high fat diet plus miglitol (HFM).
Oxygen consumption (VO2) was used to estimate metabolic rate. A thermal imaging camera was used to quantify heat
generation from interscapular brown adipose tissue. We analyzed the protein and gene expressions of UCP1 and the
expressions of four proteins related to β3-adrenergic signaling in the pathway activating UCP1 (protein kinase A (PKA),
hormone-sensitive lipase (HSL), p38 α mitogen-activated protein kinase (p38αMAPK) and peroxisome
proliferator-activated receptor gamma coactivator 1α (PGC1α)).
Results: At 8 weeks, body weight, epididymal and subcutaneous white adipose tissue and the HOMA-R value of the
HFM mice were significantly less than those of the HF mice. Food intake was not different between the HF and HFM
mice. VO2 and BAT temperature were significantly higher in the HFM mice. Miglitol significantly enhanced the gene and
protein expressions of UCP1 and the expressions of proteins related to β3-adrenergic signaling.
Conclusions: Miglitol’s anti-obesity effect was attributed to increased energy expenditure by upregulating UCP1 in BAT
(i.e., by thermogenesis) and to enhancement of β3-adrenergic signaling in BAT.
Keywords: Miglitol, Alpha-glucosidase inhibitor, Obesity, Oxygen consumption, Brown adipose tissue, Uncoupling
protein 1, β3-adrenergic signalingBackground
Obesity develops from an imbalance between energy intake
and energy expenditure [1]. At present, only medicines that
inhibit energy intake, such as appetite suppressants and
lipid absorption inhibitors, are authorized as anti-obesity
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unless otherwise stated.(FDA). Enhancement of energy expenditure has emerged
as a potential and attractive strategy for treating or pre-
venting obesity. Whereas white adipose tissue acts to store
surplus energy, brown adipose tissue (BAT) expends en-
ergy by heat production through uncoupling protein 1
(UCP1) in its mitochondria [2]. In general, it has been be-
lieved that humans lose BAT shortly after infancy. How-
ever, recent studies using positron emission tomography/
computed tomography (PET/CT) have shown that adult
humans still possess functional BAT. BAT has received
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commonly used as an anti-diabetic drug [8]. In diabetic
subjects, miglitol blunts postprandial hyperglycemia by
inhibiting alpha-glucosidase in the small intestine and
prolongs carbohydrate absorption. Recently, miglitol has
been reported to have an anti-obesity effect [9-11]. How-
ever, its mechanisms are not clear. Here we examined
the effect of miglitol on UCP1, an enzyme involved in
thermogenesis, in BAT. Our results show that migli-
tol increased energy expenditure, reduced obesity and
enhanced β3-adrenergic signaling and upregulation of
UCP1 in BAT. These data provide further support for




Four-week-old male C57BL/6 J mice were purchased from
CLEA Japan (Tokyo, Japan). Four diets were prepared: nor-
mal chow (CLEA Rodent diet CE-2: 12% of calories from
fat, 59.1% of calories from carbohydrate, 28.8% of calories
from protein), a high fat diet (HFD) (Clea High fat diet 32:
56.7% of calories from fat, 23.1% of calories from carbohy-
drate, 20% of calories from protein), normal chow contain-
ing 0.008% miglitol and HFD containing 0.008% miglitol.
A previous study of miglitol in mice [11] used a diet con-
taining 0.08% miglitol. We chose to use a lower dose be-
cause it was closer to the dose used in clinical medicine.
Mice were divided into 4 groups: a control group (NC),
which was fed normal chow, a normal chow plus miglitol
(NCM) group, which was fed the normal chow plus migli-
tol, a high fat (HF) group, which was fed the HFD, and a
high fat plus miglitol (HFM) group, which was fed the
HFD plus miglitol. The mice were kept in a temperature-
controlled room (23°C) on a 12 h light/dark cycle (lights
on 07:00 h; off 19:00 h) with free access to food and water.
Individual food intake and body weight gain were moni-
tored once a week. At 8 weeks, mice were fasted overnight
and anaesthetized with sodium pentobarbital (50 mg/kg,
i.p.) and blood was obtained by cardiopuncture. Plasma
was separated by centrifugation at 4°C and stored at −80°C
until assayed. The epididymal and subcutaneous white
adipose tissues were dissected and weighed. Interscapu-
lar brown adipose tissue and liver were immediately dis-
sected, frozen in liquid nitrogen and stored at −80°C
until further analysis. All animal experiments and care pro-
cedures were conducted in conformity with the Guidelines
of the Animal Care and Use Committee of Kyoto Prefec-
tural University of Medicine.
Plasma parameters
Blood glucose was determined with a compact glucose
analyzer Antsense II (Horiba, Kyoto, Japan). Plasma tri-
glyceride (TG) and total cholesterol (T-Cho) levels weremeasured with reagents from Wako (Osaka, Japan). Plasma
insulin level was measured by an ELISA kit (Morinaga
Institute of Biological Science, Kanagawa, Japan). Plasma
active glucagon-like peptide 1 (GLP1) levels were mea-
sured with an ELISA kit (Shibayagi, Gunma, Japan). All of
the assays were performed according to the manufac-
turer’s instructions. Serum concentration of miglitol was
measured by liquid chromatography - tandem mass spec-
trometry (LC/MS/MS).
Oxygen consumption
Oxygen consumption (VO2) was measured with an O2/
CO2 metabolism-measuring system (model MK-5000,
Muromachi-Kikai, Tokyo, Japan), which consists of two
independent 560-ml chambers (for measuring two animals
simultaneously), a suction pump and a computer for data
analysis [12]. The mice were placed in the chambers at
23°C and acclimated for more than two hours. Every three
minutes, the pump draws air from one of the chambers
for one minute at rate of a 650 ml/min to measure O2
concentration. Oxygen consumption (VO2) was calculated
as [Oa-Oc]v m−1 t−1, where Oa is the atmospheric oxygen
concentration (%) that flows into the chamber, Oc is the
oxygen concentration in the chamber (%), v is the flow
rate (650 milliliters/min), m is the mass of the mouse in
kg and t is the time in hours [13].
Interscapular temperature
Mice were fasted for 6 hours and anaesthetized (sodium
pentobarbital, 30 mg/kg, i.p.). Interscapular temperature
surrounding BAT was recorded with a thermal imaging
camera (FLIR i3, FLIR Systems, Tokyo, Japan) and analyzed
with FLIR QuickReport software.
Histology
BAT was fixed in 10% buffered formalin. Sections (5 μm)
were stained with hematoxylin and eosin. Slides were ex-
amined and photomicrographs taken under the same ex-
posure and magnification. Lipid droplets in cells of BAT
were quantified as previously described [14]. One tissue
section from each mouse was measured under blinded
conditions by one investigator (S.S.) counting the number
of nuclei surrounded by four or more lipid vacuoles/cell in
two randomly chosen areas (1600 μm2) of each section,
and averaging the results.
Western blot analysis
BAT was lysed with radioimmunoprecipitation assay (RIPA)
lysis buffer (Nacalai Tesque, Kyoto, Japan). Homogenates
were centrifuged at 10,000 × g for 10 min at 4°C and su-
pernatants were collected. Protein concentrations were
determined with a Bio-Rad protein assay kit (Bio-Rad,
Tokyo, Japan). Tissue proteins were resolved on 10%
polyacrylamide gels in the presence of sodium dodecyl
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difluoride membranes, and blocked by Blocking One
(Nacalai Tesque). The primary and secondary antibodies
were diluted with Can Get Signal (Toyobo, Osaka, Japan).
The membrane was incubated with primary antibodies
against proliferator-activated receptor gamma coacti-
vator 1α (PGC1α) (1:10,000) (Abcam, Tokyo, Japan),
UCP1 (1:15,000) (Abcam), β3-adrenergic receptor (β3AR)
(1:10,000) (Abcam), protein kinase A (PKA) (1:5,000) (Santa
Cruz Biotechnology, Santa Cruz, CA), phosphorylated-
protein kinase A (pPKA) (1:5,000) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), hormone-sensitive lipase (HSL)
(1:10,000) (Cell Signaling Technology, Tokyo, Japan),
carnitine palmitoyltransferase1 (CPT1) (1:5,000) (Lifespan
Biosciences, Seattle, WA), p38α mitogen-activated protein
kinase (p38αMAPK) (1:5,000) (Cell Signaling Technol-
ogy), and β-actin (1:5,000) (Cell Signaling Technology).
Secondary antibody consisted of a 1:15,000 dilution of
HRP-conjugated donkey anti-rabbit IgG (for PGC1α,
UCP1, β3AR, PKA, pPKA, HSL, CPT1, p38αMAPK) (GE
Healthcare, Tokyo, Japan) or HRP-conjugated sheep anti-
mouse IgG (for β-actin) (GE Healthcare). The immuno-
complexes were detected using an enhanced HRP-luminol
chemiluminescence system (ECL prime) (GE Healthcare)
and subjected to autoradiography (New Amersham Hyper-
film) (GE Healthcare). Signals on the immunoblot were
quantified using the NIH Image computer program (NIH,
Bethesda, MD, version 1.45). To compare the results for
protein expression, we assigned a value of 1 to expression
in BAT from control mice.
Cyclic AMP (cAMP) assay
The selective β3-adrenergic receptor agonist CL316,243
(Sigma, Tokyo, Japan) (2 mg/kg/body weight) and saline
was given by intraperitoneal injection 6 h before the end
of the experiment. The amount of cAMP in BAT was
measured by a cAMP assay kit (R&D Systems, Minneapolis,
MN) according to the manufacturer’s instructions.
Quantitative real-time PCR
Total RNA from BAT and liver were isolated using
a NucleoSpin RNA II kit (Macherey-Nagel, Düren,
Germany). Template cDNA synthesized from 500 ng
total RNA with random hexamer primers was used as the
template for each reaction with a SuperScript First-Strand
Synthesis System (Invitrogen Life Technology, Osaka,
Japan). Quantitative real-time PCR (qRT-PCR) was per-
formed using a SYBR Green master mix (Takara, Shiga,
Japan) with 10 μM of each primer in an AB 7300 Real-
Time PCR System (Applied Biosystems, Tokyo, Japan).
Amplification was performed with the following protocol:
40 cycles (5 sec at 95°C and 31 sec at 60°C) after an initial
activation step for 30 sec at 95°C. Primer sequences
were shown as follows: β-actin (BAT), forward primer:5′-GAAATCGTGCGTGACATCAAAG-3′, reverse primer:
5′-TGTAGTTTCATGATGCCACAG-3′; β-actin (liver),
forward primer: 5′-GGCTGTATTCCCCTCCATCG-3′, re-
verse primer: 5′-CCAGTTGGTAACAATGCCATGT-3′;
PGC1α, forward primer: 5′-TGAACGCACCTTAAGTGT
GGAA-3′, reverse primer: 5′- GGGTTATCTTGGTTGG
CTTTATGA-3′; UCP1, forward primer: 5′- AGGCTTCC
AGTACCATTAGGT -3′, reverse primer: 5′-CTGAGTGA
GGCAAAGCTGATTT-3′; CPT1, forward primer: 5′-CCA
ATCATCTGGGTGCTGG-3′, reverse primer: 5′-AAGA
GACCCCGTAGCCATCA-3′; glucokinase (GK), forward
primer: 5′-CAACTGGACCAAGGGCTTCAA-3′, reverse
primer: 5′-TGTGGCCACCGTGTCATTC-3′. β-actin was
chosen as an internal standard.
Statistical analysis
Data are shown as means ± SEM. Single-group data were
assessed using Student’s t-test. Repeated measurements
of analysis of variance (ANOVA) with Tukey-Kramer post
hoc comparisons were performed for multiple compari-
sons. P values less than 0.05 were considered statistically
significant.
Results
Miglitol reduced body weight gain and increased energy
expenditure in high fat diet-induced obese mice
The body weight of mice fed a high fat diet (HF mice)
(27.3 ± 0.4 g at 8 weeks) was significantly greater than
that of mice fed normal chow (p < 0.05) (control mice)
(21.5 ± 0.2 g). The body weight of mice fed the high fat
diet plus miglitol (HFM mice) (25.8 ± 0.4 g) was sig-
nificantly less than that of HF mice (p < 0.05) (Table 1,
Figure 1A) even though the two groups consumed the
same amount of food energy (Figure 1B, C). On the other
hand, miglitol did not affect the body weight under the con-
dition of normal chow (Table 1, Figure 1A). The miglitol-
treated mice did not manifest any of the common adverse
effects of miglitol, such as gastrointestinal abnormalities,
diarrhea or anorexia. Oxygen consumption (VO2), an indir-
ect measurement of metabolism, was significantly increased
in HFM mice compared to HF mice in both the dark and
light phases (p < 0.05) (Figure 2). By contrast, VO2 was
not different between NC and NCM mice. Interscapular
BAT temperature in HFM mice (34.7 ± 0.7°C) was sig-
nificantly higher (p < 0.05) than that in HF mice (31.5 ±
0.3°C) and was significantly higher (p < 0.05) than the
temperatures in NC mice (30.0 ± 0.6°C) and NCM mice
(30.7 ± 0.5°C) (Figure 3).
Miglitol ameliorated insulin resistance in high fat
diet-induced obese mice
Blood glucose and plasma T-Cho levels were signifi-
cantly higher in HF mice than in NC and NCM mice.
Blood glucose levels were significantly lower in HFM mice
Table 1 Metabolic parameters at 8-weeks-old mice
n NC NCM HF HFM
Body weight (g) 10-11 21.5 ± 0.2 22.2 ± 0.2 27.3 ± 0.4 a, b 25.8 ± 0.4 a, b, c
Glucose (mg/dl) 5 118 ± 6.6 129 ± 15.4 282 ± 4.1 a, b 240 ± 9.1 a, b, c
Total cholesterol (mg/dl) 5-7 62 ± 4.7 68 ± 4.9 150 ± 7.2 a, b 141 ± 4.2 a, b
Triglyceride (mg/dl) 6 42 ± 8.4 45 ± 5.7 42 ± 4.9 46 ± 5.2
Insulin (μU/ml) 5 5.3 ± 1.2 3.4 ± 0.5 12.3 ± 1.9 a, b 6.7 ± 1.2
HOMA-R 5 1.4 ± 0.3 1.1 ± 0.3 8.4 ± 1.3 a, b 4.0 ± 0.7 a, b, c
Weight of epididymal white adipose tissue (g) 9-14 0.27 ± 0.02 0.28 ± 0.01 1.1 ± 0.08 a, b 0.85 ± 0.04 a, b, c
Weight of subcutaneous white adipose tissue (g) 6 0.3 ± 0.03 Not measured 1.5 ± 0.15 a 0.98 ± 0.12 a, c
Active glucagon-like peptide1 (pg/ml) 8-9 54.8 ± 7.9 61.1 ± 4.9 66 ± 7.5 76.9 ± 14.4
Concentration of miglitol (μmol/L) 3-4 Not measured 0.06 ± 0.02 Not measured 0.26 ± 0.13
Values are means ± SE for 3–14 mice. Blood samples were collected under fasting conditions. aP < 0.05, vs mice fed normal chow diet (NC). bP < 0.05, vs mice fed
normal chow diet plus miglitol (NCM). cP < 0.05, vs mice fed high-fat diet alone (HF).
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groups. The HOMA-R value, an index of insulin resist-
ance, was significantly elevated in HF mice and signifi-
cantly lowered by miglitol (control 1.4 ± 0.3 vs. NM 1.1 ±
0.3 vs. HF 8.4 ± 1.3 vs. HFM 4.0 ± 0.7) (CC or NC vs. HF,
p < 0.05; HF vs. HFM, p < 0.05). The masses of epididymal
and subcutaneous white adipose were lower in the HFM
mice than in the HF mice (Table 1).
Miglitol enhances the secretion of active glucagon-
like-peptide1 (GLP1) in obese humans (see “Discussion”
section). Because GLP1 decreases food intake, many cli-
nicians attribute miglitol’s anti-obesity effect to suppres-
sion of food intake. However, the active GLP1 level did
































Figure 1 Effect of miglitol on body weight gain. A: Body weight chang
5–11 mice. aP < 0.05, vs mice fed normal chow diet (NC). bP < 0.05, vs mice
high-fat diet alone (HF).Miglitol decreased the number of lipid droplets in BAT
cells of HF mice
To evaluate the degree of lipolysis, we investigated the
microscopic appearance of BAT. The HFD increased the
number of lipid droplets in cells of BAT, while miglitol sig-
nificantly decreased the number of lipid droplets in cells of
BAT (NC 9.1 ± 0.5 vs. HF 4.3 ± 0.2 vs. HFM 7.0 ± 0.3 cells/
area) (NC vs. HF or HFM, p < 0.05; HF vs. HFM, p < 0.05)
(Figure 4).
Miglitol enhanced the gene and protein expressions of
UCP1 in BAT of HFM mice
The main function of BAT is thermogenesis, which is me-

































































NC NCM HF            HFM
(n=5)            (n=5)  (n=5)         (n=5)
a, b a, b
e. B: Weekly food intake. C: Total food intake. Values are means ± SE for
fed normal chow diet plus miglitol (NCM). cP < 0.05, vs mice fed
Figure 2 Effect of miglitol on energy expenditure. A: 22-h Oxygen consumption. B: Oxygen consumption in dark and light phases. Values are
means ± SE for 3–10 mice. aP < 0.05, vs mice fed normal chow diet (NC). bP < 0.05, vs mice fed normal chow diet plus miglitol (NCM). cP < 0.05, vs
mice fed high-fat diet alone (HF).
NC        NCM       HF        HFM






























Figure 3 Effect of miglitol on BAT temperature. A shows representative infrared thermal image of normal chow diet mice (NC), miglitol-treated
normal chow diet mice (NCM), high-fat diet mice (HF) and miglitol-treated high-fat diet mice (HFM). B: Interscapular temperature was measured. Values
are means ± SE for 4–5 mice. aP < 0.05, vs mice fed normal chow diet (NC). bP < 0.05, vs mice fed normal chow diet plus miglitol (NCM). cP < 0.05, vs
mice fed high-fat diet alone (HF).























NC HF                        HFM
(n =5)                  (n=6)                     (n=6)
a, c
Figure 4 Effect of miglitol on the number of lipid droplets in BAT cells. Histology of BAT was examined by HE staining (Scale bar = 40 μm).
A, B and C show the representative histology of normal chow diet mice, high-fat diet mice and miglitol-treated high-fat diet mice, respectively.
D: The number of cells/area was counted. Values are means ± SE for 5–6 mice. aP < 0.05, vs mice fed normal chow diet (NC). cP < 0.05, vs mice fed
high-fat diet alone (HF).
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gene. We evaluated gene and protein expressions of PGC1α
and UCP1. The mRNA levels of PGC1α showed no dif-
ferences between the four groups. However, the level of
PGC1α protein of HFM mice was 1.4-fold higher than that
of HF mice (p < 0.05) (Figure 5A, B). The expression of
UCP1 mRNA in HFM mice was 1.5-fold higher than that
of HF mice (p < 0.05). Miglitol did not enhance the expres-
sion of UCP1 mRNA in normal chow-fed mice. The level
of UCP1 protein in HF mice was 1.7-fold higher than that
of control mice (p < 0.05), and the level of UCP-1 pro-
tein of HFM mice was 1.2-fold higher than that of HF
mice (p < 0.05) (Figure 5A, B). We measured CPT1 ex-
pression in BAT to evaluate mitochondrial β-oxidation.
The expressions of CPT1 mRNA and protein were sig-
nificantly increased in both HF mice and HFM mice as
compared with control mice. (Figure 6A, B).
Miglitol enhanced β3-adrenergic signaling in BAT of
HFM mice
β3-adrenergic signaling through the β3-adrenergic recep-
tor (β3AR) activates UCP1 and thus has a role in reducing
obesity. The protein expression of β3AR was not signifi-
cantly different between HF and HFM mice (Figure 7A).
However, the protein expressions of PKA, HSL and p38α
MAPK of HFM mice were significantly increased as com-
pared with HF mice (1.7, 1.2 and 1.5-fold, respectively)
(p < 0.05) (Figure 7B-D). To test whether miglitol’s upregu-
lation of UCP1 expression was mediated by β3-adrenergic
signaling, we measured the effect of a selective β3ARagonist (CL316,243). CL316,243 induced greater amounts
of cAMP and pPKA protein in HFM mice than in HF mice
(Figure 8A, B).
Hepatic glucokinase expression did not affect
thermogenesis in BAT
During the course of this study, it was reported that hep-
atic glucokinase (GK) expression suppressed thermogen-
esis in BAT [15]. This raised the possibility that miglitol
acts by suppressing liver GK expression. However, miglitol
did not suppress GK mRNA expression (Figure 9).
Discussion
Our data show that miglitol reduced body weight gain and
insulin resistance, consistent with a previous study using
spontaneous-onset obese type 2 diabetes mice [11]. Recent
studies have focused on BAT as a target of treatment for
obesity [3,4,16]. We hypothesized that the reason of sup-
pressed body weight gain observed in miglitol-treated
mice was the upregulation of energy expenditure. BAT
produces heat by non-shivering thermogenesis to main-
tain body temperature [3]. The key component of this
process is UCP1. UCP1, the archetypal UCP, is uniquely
expressed in mitochondria of brown adipocytes. UCP1 un-
couples adenosine-5′-triphosphate (ATP) synthesis from
substrate oxidation in brown adipocytes [17]. When UCP1
is activated, chemical energy is dissipated as heat without
ATP synthesis. The upregulation of UCP1 expression
indicates increased thermogenesis and energy expend-
















































Figure 5 Effect of miglitol on the expressions of PGC1α and UCP1 in BAT. A: Real-time PCR experiments. B: Western blot analysis. Values are
means ± SE for 5–7 mice. aP < 0.05, vs mice fed normal chow diet (NC). bP < 0.05, vs mice fed normal chow diet plus miglitol (NCM). cP < 0.05, vs
mice fed high-fat diet alone (HF).
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ulated UCP1 in BAT of high fat diet-induced obese mice.
Consistent with increased UCP1 expression, oxygen con-
sumption was increased in HFM mice (Figures 2 and 5).
Miglitol induced an increased interscapular temperature,
which can be explained by its stimulation of UCP1 expres-
sion in BAT (Figure 3). Brown adipocytes contain a large


























Figure 6 Effect of miglitol on the expression of CPT1. A: Real-time PCR
mice. aP < 0.05, vs mice fed normal chow diet (NC). cP < 0.05, vs mice fed hsympathetic nervous system (SNS). SNS nerve terminals of
BAT release noradrenaline, which activates β-adrenergic
receptors and a cascade of events leading to mitochondrio-
genesis and increased expression of UCP1. Brown adipo-
cytes express various adrenergic receptors that include the
α1- and β3- receptors. β3-adrenergic receptor (β3AR) is, at
least in rodents, the main adrenergic receptor in driving



















experiments. B: Western blot analysis. Values are means ± SE for 5–6



























































NC HF          HFM
(n=6)             (n=6)             (n=5) 
NC HF HFM
(n=6)              (n=6)          (n=5) 
NC   HF                 HFM
(n=6) (n=6) (n=5)
NC HF             HFM




Figure 7 Effect of miglitol on β3-adrenergic signaling. Protein expressions of β3-adrenergic signaling in BAT were analyzed. A-D: Western blot
analysis. Values are means ± SE for 5-6mice. aP < 0.05, vs mice fed normal chow diet (NC). cP < 0.05, vs mice fed high-fat diet alone (HF).
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tivity, which promotes synthesis of cAMP. Increased
sympathetic stimulation induces β3AR activation, in-
creased cAMP generation and subsequent activation of
PKA [19]. The protein levels of PKA were higher in HFM
mice than in HF mice in our experiment (Figure 7B),
which suggests that the upregulation of UCP1 observed in
our study involved β3-adrenergic signaling. To confirm
that upregulation of UCP1 involves β3-adrenergic signal-
ing, we evaluated the downstream signaling of PKA.
PKA induces lipolysis by activating hormone-sensitive
lipase (HSL). HSL releases free fatty acids from intracel-
lular lipid stores [19], which are then transformed into
acyl-CoA. Acyl-CoA is combined with carnitine by CPT1
and transported into the mitochondrial matrix as acyl-
carnitine. Acyl-carnitine is converted back to acyl-CoA,
which can then enter the fatty acid β-oxidation pathway.
Free fatty acids not only act as substrates for β-oxidationbut also stimulate UCP1 activity [17,19]. The expressions
of CPT1 mRNA and protein were not significantly dif-
ferent between HF mice and HFM mice in our study
(Figure 6A, B), which suggests that the β-oxidation ac-
tivity was similar in the two groups. The HFM mice had
higher HSL protein levels than the HF mice. The find-
ings that miglitol decreased the number of lipid droplets
in BAT cells (Figure 4) and increased the protein expres-
sion of HSL (Figure 7C) suggest that lipolysis was acti-
vated by miglitol under the high-fat diet. The lipolysis
induced by miglitol activated UCP1.
The chronic effects of PKA activation include mito-
chondrial biogenesis and increased UCP1 gene expression
[19]. p38αMAPK is reported to induce UCP1 expression
by stimulating the SNS [20-22]. In mouse adipocytes
and animal models, β-AR stimulation triggers a kinase
cascade from PKA to p38MAPK, which phosphorylates











































Figure 8 Effect of miglitol on cAMP and pPKA in the presence of a β3-adrenergic receptor agonist. A: cAMP amount in BAT. B: Western
blot analysis. Values are means ± SE for 4–5 mice. cP < 0.05, vs mice fed high-fat diet alone (HF). dP < 0.1, vs mice fed high-fat diet alone (HF).
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UCP1 gene expression [23]. These events also contribute
to the orchestrated response to increase mitochondrio-
genesis and the overall thermogenic capacity of brown
adipocytes. The finding that protein levels of p38α MAPK
and PGC1α were higher in HFM mice than in HF mice
(Figure 5B, Figure 7D) suggests that the gene expres-
sion of UCP1 was upregulated through the PKA-p38
MAPK-PGC1α cascade by miglitol in high fat diet-
induced obese mice.Figure 9 Effect of miglitol on the gene expression of liver
glucokinase (GK). Real-time PCR experiments. Values are means ± SE
for 5-6mice. aP < 0.05, vs mice fed normal chow diet (NC). cP < 0.05,
vs mice fed high-fat diet alone (HF).A β3AR agonist (CL316,243) was found to increase
PGC1α mRNA and UCP1 mRNA in 4–6 hours [24,25].
In our study, CL316,243 produced greater amounts of
cAMP and pPKA protein in HFM mice than in HF mice
(Figure 8A, B), confirming that miglitol enhanced β3-
adrenergic signaling under the high fat diet.
Glucagon-like peptide 1 (GLP1) is secreted from L
cells in the intestine, and promotes insulin secretion in a
glucose-dependent manner following ingestion of carbo-
hydrate [26]. GLP1 receptor agonists have been used for
the treatment of type 2 diabetes patients in recent years.
GLP1 has the potential to be used as an anti-obesity drug
[27]. GLP1 not only stimulates insulin secretion but also
decreases appetite and reduces food intake when adminis-
tered either peripherally or directly into the central nerve
system [28]. Though miglitol enhances GLP1-secretion in
obese humans [29-31], plasma active GLP1 levels in the
HF and HFM mice in this study were not significantly dif-
ferent (Table 1), which suggests that GLP1 did not partici-
pate in the reduction of obesity in this study.
It remains unclear how miglitol induces thermogenesis
in BAT. One possibility is that miglitol stimulates the
SNS, which is known to enhance β3-adrenergic signaling
[19], which in turn induces thermogenesis in BAT. One
way in which miglitol could stimulate the SNS is by sup-
pressing hepatic glucokinase (GK) expression [15]. How-
ever, miglitol did not suppress GK mRNA expression in
our study (Figure 9).
β3AR agonists increase oxygen consumption and lead
to weight loss in obese rodents [32,33]. However, β3AR
stimulants have not yet become available, partly because
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[34]. Miglitol has few side effects in humans, and is feas-
ible for long-term use as an oral drug. The adverse effects
of miglitol are mainly minor gastrointestinal symptoms. If
these side effects are acceptable, miglitol has promise as
an anti-obesity drug. If the side effects are not acceptable,
another approach is to develop new therapeutics based on
the mechanisms of miglitol.
Conclusions
Miglitol 1) increased energy expenditure, 2) had an anti-
obesity effect in high fat diet-induced obese mice, 3) en-
hanced β3-adrenergic signaling and 4) upregulated UCP1
in BAT under the condition of a high fat diet. These find-
ings suggest that miglitol has the potential to be a thera-
peutic for the treatment of obesity.
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